Michael A Metzger insider trades

Open-market stock purchases and sales by Michael A Metzger, Chief Executive Officer at Syndax Pharmaceuticals Inc, from SEC Form 4 filings since Dec 1, 2010.

Recent trades

DateStockTradeValue
Jul 8, 2026SNDX Syndax Pharmaceuticals IncSold$785K
Jul 8, 2026SNDX Syndax Pharmaceuticals IncBought (not open market)$207K
Jul 8, 2026SNDX Syndax Pharmaceuticals IncBought (not open market)—
Jun 1, 2026SNDX Syndax Pharmaceuticals IncSold$130K
Mar 24, 2026PYXS Pyxis Oncology, IncBought (not open market)—
Feb 9, 2026SNDX Syndax Pharmaceuticals IncSold$361K
Feb 6, 2026SNDX Syndax Pharmaceuticals IncSold$153K
Feb 4, 2026SNDX Syndax Pharmaceuticals IncBought (not open market)—
Feb 4, 2026SNDX Syndax Pharmaceuticals IncBought (not open market)—
Feb 4, 2026SNDX Syndax Pharmaceuticals IncBought (not open market)$9M

Companies traded

  • SNDX Syndax Pharmaceuticals Inc: 34 sales, last Jul 8, 2026
  • PYXS Pyxis Oncology, Inc: other filings, last Mar 24, 2026
  • CTIC CTI Biopharma Corp: 12 sales, last Jun 26, 2023
  • RGDO Regado Biosciences Inc: other filings, last Dec 3, 2014
  • RGDX Response Genetics Inc: 1 buy, last Jul 30, 2012

Get free alerts when Michael A Metzger files a new trade →